PMID- 11213859
OWN - NLM
STAT- MEDLINE
DCOM- 20010503
LR  - 20190915
IS  - 0277-0008 (Print)
IS  - 0277-0008 (Linking)
VI  - 21
IP  - 2
DP  - 2001 Feb
TI  - Dosing and monitoring of low-molecular-weight heparins in special populations.
PG  - 218-34
AB  - As a result of numerous clinical trials and meta-analyses supporting the superior 
      efficacy and relative safety of low-molecular-weight heparins (LMWHs) compared 
      with unfractionated heparin (UFH), LMWHs are emerging as the antithrombotic 
      agents of choice for the prevention and treatment of deep vein thrombosis and 
      pulmonary embolism. In addition, data indicate that enoxaparin given with 
      low-dosage aspirin is more effective than UFH in treating acute coronary 
      syndromes. Anti-Xa activity can be used as a biologic marker of LMWH activity. 
      Because of the more predictable anticoagulant response to subcutaneous 
      administration of LMWHs compared with UFH, routine monitoring of anti-Xa activity 
      in clinically stable adults with uncomplicated disease is not recommended. 
      Because the optimal dosage of LMWHs has not been established for patients with 
      renal insufficiency or extremes of body weight, during pregnancy, or for 
      children, anti-Xa activity monitoring may be warranted in these subsets.
FAU - Duplaga, B A
AU  - Duplaga BA
AD  - Pharmacy Services, Washington County Health System, Hagerstown, Maryland, USA.
FAU - Rivers, C W
AU  - Rivers CW
FAU - Nutescu, E
AU  - Nutescu E
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Pharmacotherapy
JT  - Pharmacotherapy
JID - 8111305
RN  - 0 (Anticoagulants)
RN  - 0 (Heparin, Low-Molecular-Weight)
RN  - EC 3.4.21.6 (Factor Xa)
SB  - IM
MH  - Anticoagulants/*administration & dosage/pharmacokinetics
MH  - Body Weight/drug effects/physiology
MH  - Child
MH  - Child, Preschool
MH  - Clinical Trials as Topic
MH  - Coronary Disease/blood/*drug therapy
MH  - *Drug Monitoring
MH  - Factor Xa/*drug effects/metabolism
MH  - Female
MH  - Heparin, Low-Molecular-Weight/*administration & dosage/pharmacokinetics
MH  - Humans
MH  - Pregnancy/blood/*drug effects
MH  - Renal Insufficiency/*blood
MH  - Venous Thrombosis/blood/*drug therapy
RF  - 130
EDAT- 2001/02/24 12:00
MHDA- 2001/05/05 10:01
CRDT- 2001/02/24 12:00
PHST- 2001/02/24 12:00 [pubmed]
PHST- 2001/05/05 10:01 [medline]
PHST- 2001/02/24 12:00 [entrez]
AID - 10.1592/phco.21.2.218.34112 [doi]
PST - ppublish
SO  - Pharmacotherapy. 2001 Feb;21(2):218-34. doi: 10.1592/phco.21.2.218.34112.